Page 33 - Read Online

Waterford et al. Vessel Plus 2022;6:28 https://dx.doi.org/10.20517/2574-1209.2021.115 Page 11 of 12

Atrial Fibrillation). Eur Heart J 2006;27:1979-2030. DOI PubMed
16. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients
undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery)
study. Circulation 2006;114:1455-61. DOI PubMed
17. Chen WT, Krishnan GM, Sood N, Kluger J, Coleman CI. Effect of statins on atrial fibrillation after cardiac surgery: a duration- and
dose-response meta-analysis. J Thorac Cardiovasc Surg 2010;140:364-72. DOI PubMed
18. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9. DOI PubMed
19. White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI. Effect of preoperative angiotensin converting enzyme inhibitor or
angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation
suppression trials II and III. Eur J Cardiothorac Surg 2007;31:817-20. DOI PubMed
20. El-Haddad MA, Zalawadiya SK, Awdallah H, et al. Role of irbesartan in prevention of post-coronary artery bypass graft atrial
fibrillation. Am J Cardiovasc Drugs 2011;11:277-84. DOI PubMed
21. Mekontso-dessap A, Houël R, Soustelle C, Kirsch M, Thébert D, Loisance DY. Risk factors for post-cardiopulmonary bypass
vasoplegia in patients with preserved left ventricular function. Ann Thorac Surg 2001;71:1428-32. DOI PubMed
22. Rodriguez-Gabella T, Catalá P, Muñoz-García AJ, et al. Renin-angiotensin system inhibition following transcatheter aortic valve
replacement. J Am Coll Cardiol 2019;74:631-41. DOI PubMed
23. Kaufman ES, Zimmermann PA, Wang T, et al; Atrial fibrillation follow-up investigation of rhythm management investigators. Risk of
proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study: a multivariate analysis.
J Am Coll Cardiol 2004;44:1276-82. DOI PubMed
24. Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug
Saf 2010;33:539-58. DOI PubMed
25. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007;298:1312-22. DOI
PubMed
26. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007;356:935-41. DOI PubMed
27. Hamilton D Sr, Nandkeolyar S, Lan H, et al. Amiodarone: a comprehensive guide for clinicians. Am J Cardiovasc Drugs 2020;20:549-
58. DOI PubMed
28. Meng X, Mojaverian P, Doedée M, et al. Bioavailability of amiodarone tablets administered with and without food in healthy subjects.
Am J Cardiol 2001;87:432-5. DOI PubMed
29. Mitchell LB, Wyse DG, Gillis AM, Duff HJ. Electropharmacology of amiodarone therapy initiation. Time courses of onset of
electrophysiologic and antiarrhythmic effects. Circulation 1989;80:34-42. DOI PubMed
30. Avedissian SN, Pham M, Joshi MD, et al. Pharmacokinetic disposition of amiodarone when given with an intralipid rescue strategy.
Pharmaceutics 2021;13:539. DOI PubMed PMC
31. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular
arrhythmias and the prevention of sudden cardiac death: a report of the american college of cardiology/American Heart Association
task force on clinical practice guidelines and the heart rhythm society. Circulation 2018;138:e272-391. DOI
32. Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther
2013;37:1132-56. DOI PubMed
33. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology/American Heart Association Task Force on Practice
Guidelines, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association, Heart Rhythm
Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for
Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation):
developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e257-
354. DOI PubMed
34. Hauser TH, Pinto DS, Josephson ME, Zimetbaum P. Early recurrence of arrhythmia in patients taking amiodarone or class 1C agents
for treatment of atrial fibrillation or atrial flutter. Am J Cardiol 2004;93:1173-6. DOI PubMed
35. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999;100:2025-34. DOI PubMed
36. Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and thyroid physiology, pathophysiology, diagnosis and
management. Trends Cardiovasc Med 2019;29:285-95. DOI PubMed PMC
37. Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med 2003;348:2646-55. DOI PubMed
38. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with
amiodarone. Practice Guidelines Subcommittee, North American Society of pacing and electrophysiology. Arch Intern Med
2000;160:1741-8. DOI PubMed
39. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009;16:43-8. DOI PubMed PMC
40. Olshansky B, Sami M, Rubin A, et al; NHLBI AFFIRM Investigators. Use of amiodarone for atrial fibrillation in patients with
preexisting pulmonary disease in the AFFIRM study. Am J Cardiol 2005;95:404-5. DOI PubMed
41. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial
fibrillation: a prospective and randomized study. Circulation 2002;106:331-6. DOI PubMed